You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Catheter Based Cardiovascular Device Retrieval System
SBC: Onocor LLC Topic: NHLBIDuring the past decade there has been an exponential growth in the numberscope and complexity of catheter based interventions for structural heart diseaseTranscatheter aortic valve replacementTAVRendovascular aneurysm repairEVARvena caval filters and intracardiac defect closure are all well developed and growing treatment strategiesThe recent FDA approval of left atrial appendageLAAocclusion for a ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Measuring Bladder Permeability with MRI Using a Novel Contrast Agent Formulation
SBC: Lipella Pharmaceuticals Inc. Topic: 300ABSTRACT This Phase II SBIR proposal leverages the progress made in Phase I on the development of a novel contrast mixture enhanced Tweighted MRI technique as a safesensitiveand objective diagnostic test for the increased permeability in the luminal surface of the urinary bladder in Interstitial Cystitis Bladder Pain SyndromeIC BPSpatientsThe purpose of having such a test is ultimately to allow cl ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Myocardial delivery of MMP inhibiting hydrogels
SBC: Prohibix, LLC Topic: NHLBIABSTRACTOvermillion people in the United States currently suffer from heart failure caused by a myocardial infarctionMIand more thansurvivable MIs occur each yearThese troubling statistics amount to an economic burden of over $billion annuallyCurrent clinical treatments for MI include coronary stents and bypass surgeries to overcome the blocked artery and pharmacologic prescription to lessen the w ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIAIDThe ultimate goal of this Phase I application is to develop novel small moleculebroad spectrum therapeutics against viral infections caused by filoviruses that depend on the PPxY L domain motif for virus egress and spread of infectionEbolaEBOVand MarburgMARVviruses are highly pathogenic and classified as Category Ahigh priority bioterror pathogensAs there are no commercially available therapeutic ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Trigriluzole for the Treatment of Cocaine Addiction
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIDAWe have discovered trigriluzoleTRLZa tripeptide prodrug improved version of the market drug riluzoleRLZThe glutamic acid lowering properties of RLZ are ideally suited for the treatment of cocaineCOCaddictionand TRLZ is a major advance in delivering riluzole in vivo as validated in multiple in vivo studies in mouseratcynomolgous monkey and humansPhase I PKsafety and tolerability clinical trialTRLZ ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Graft-protective properties of LGM2605 in Lung Transplantation
SBC: Lignamed, LLC Topic: NHLBILignaMedLLC is developing LGMa novel medical device that will be administered via an FDA approved ex vivo lung perfusion deviceEVLPto improve lung function parameters of ex vivo donor lungs in advance of transplant surgeryPer FDA device regulations LGMwill be fully flushed and cleared from the donor lung prior to transplantThe major challenge with lung transplantation is the oxidative damage that ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Automated Object Contouring Methods and Software for Radiotherapy Planning
SBC: Quantitative Radiology Solutions LLC Topic: 102Abstract In 2015, 1,658,370 new cancer cases are estimated to occur in the US, where nearly two-thirds will have radiation therapy (RT). Given that there are over 2,300 RT centers in the US, and current systems for contouring organs at risk (OARs) rely mostly on manual methods, there is a strong commercial opportunity for producing a software system that can contour OARs in medical images at a hig ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health